Epigenomics AG

medical devices

About

Epigenomics AG is a molecular diagnostics company founded in 1998 and based in Berlin, Germany, with a subsidiary in Seattle, Washington. The company is publicly traded on the Frankfurt Stock Exchange under the ticker ECX. Epigenomics specializes in developing and commercializing minimally invasive diagnostic tests for oncology, focusing on DNA methylation-based biomarkers that aid in the detection and diagnosis of various cancers. Key products include Epi proColon, a blood-based test for early colorectal cancer detection, and Epi proLung, which assists in lung cancer diagnosis. The company also works on the PITX2 biomarker for prostate cancer prognosis. Epigenomics aims to make methylation testing routine in clinical laboratories and has contributed significantly to biomarker science, with over 60 peer-reviewed publications in the last decade. Its target customers include healthcare providers, clinical laboratories, and oncology specialists in Europe and North America.

Technologies

Outlook Microsoft Office 365 WordPress.org Mobile Friendly Apache Bootstrap Framework Remote

Keywords

epigenetics cancer medical devices dna methylation cancer diagnostics medical equipment manufacturing biotech holding company healthcare b2b epigenetic markers biotech research and development in the physical engineering and life sciences medical technology medical diagnostics cancer detection minimally invasive diagnostics regulatory compliance portfolio management biotechnology investments asset management blood-based cancer tests investments in biotech data protection blood tests for cancer detection investment management blood-based diagnostics liquid biopsy patient care

Location

11055 Flintkote Ave, San Diego, California, United States, 92121

Related Companies

Companies in the same industry